Laboratoires Delbert, SAS

Laboratoires Delbert, SAS is a pharmaceutical company that specializes in the production and preservation of essential medications, focusing on addressing critical patient needs and ensuring the availability of therapeutic alternatives in Europe. Laboratoires Delbert, SAS was founded in 2002 and is headquartered in Paris, France. The company focuses on the manufacturing of essential medicines that the pharmaceutical industry has abandoned. In April 2023, a minority stake was acquired by Vivalto Partners and the management team, marking a strategic shift in the company’s ownership structure.

The founder's individual history is not publicly available. Since its inception, the company has engaged in 2 funding deals, with the latest round being a BUYOUT of EUR 40. 00 mn, bringing the total amount raised to EUR 40. 00 mn.

Delbert Pharma specializes in the production and preservation of essential medicines that have been abandoned by the pharmaceutical industry, thereby addressing critical patient needs, particularly in areas where no therapeutic alternatives exist. The company focuses on safeguarding older drugs that are considered vital for patient care and works to relocate the production of these medicines to Europe, enhancing the quality and continuity of treatment. Delbert Pharma is also committed to repositioning certain essential molecules for new indications, with a particular emphasis on rare diseases. Their primary customers include healthcare professionals, hospitals, and pharmacies across European markets, fulfilling unmet medical needs by ensuring the availability of these critical medications.

In 2023, Laboratoires Delbert, SAS reported a revenue of EUR 18,129,471. 10 and an EBITDA of EUR 5,578,557. 90. The company generates revenue through direct partnerships with healthcare providers, hospitals, and pharmacies, facilitating the distribution of their pharmaceutical products.

Laboratoires Delbert operates on a business-to-business (B2B) model, allowing for tailored agreements with healthcare institutions that prioritize the acquisition of essential medications. The recent funding round in April 2023 will enable Laboratoires Delbert, SAS to focus on development, support the growth of its activities, and contribute to addressing drug shortages. The company plans to introduce new products designed to expand its portfolio and meet emerging healthcare needs. Additionally, Laboratoires Delbert aims to penetrate new geographic markets within Europe, enhancing its distribution network and ensuring broader access to its essential medicines.